Greg Cima

The company raised $57.5 million in February through a public offering, and the proceeds will be used to support commercial expansion in the US and EU.

The precision cancer business of PHC Holdings anticipates an increase in cancer cases and is expanding its digital pathology and immunohistochemistry instrument lineup.

The firm is preparing for a trial to show the efficacy of its CyPath Lung test and support a submission to the US Food and Drug Administration for marketing clearance.

The firm's test will be used to aid the detection of cancer in patients with dense breast tissue, which can be more difficult to analyze with mammography alone.

The Santa Clara, California-based firm said that its diagnostics and life sciences revenues rose 4 percent year over year.

The firm said that its MyProstateScore 2.0 test delivers equivalent performance with samples collected at home or collected following digital rectal examination.

The company aims to soon launch two tests to aid the treatment of dermatomycosis and is developing other tests for healthcare-acquired infections and lung diseases.

Recent study results show that the single-target DNA methylation test performed with a negative predictive value of 97.6 percent.

The digital pathology software developer is raising funding that would help it to increase its head count and support its Aiosyn Mitosis Breast application.

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.